Warsaw/Monaco, 28 October 2025

Carlson Investments SE proudly highlights the latest achievements of portfolio company Bioaccure, marking a pivotal moment in the commercialization of its PCR.smart real-time diagnostic platform. Over the past 12 months, Bioaccure has advanced from intensive R&D into active market rollout, securing new patents, expanding its technology pipeline, and strengthening relationships with distributors and industry partners.

The company’s compact PCR.smart platform — enabling real-time molecular diagnostics directly at the point of sample collection — has drawn growing attention from the food safety, veterinary, and agricultural sectors. In recent months, Bioaccure has presented its solutions to distributors and practitioners at leading industry events, receiving strong validation from end users impressed by the platform’s versatility and performance.
After securing a Polish patent for the core of its PCR.smart technology, Bioaccure has now been granted a US patent, with its EU application in final review. In parallel, the company has filed two new international patent applications, one covering a globally unique proprietary test for food safety applications. With new patents secured, commercialization underway, and growing international interest, Bioaccure is entering a decisive stage of development. Bioaccure CEO Aleksander Sienkiewicz shares:

“It is a wonderful feeling when, during discussions with our market partners, both on the distribution side and among subcontractors, we continue to experience their surprise at how innovative and unique our diagnostic platform is.”

About Bioaccure
Bioaccure is a molecular diagnostics innovator specializing in real-time PCR platforms for field and industrial use. Its patented PCR.smart system combines portability, accuracy, and speed to deliver lab-quality results in agriculture, veterinary medicine, and food safety applications.

About Carlson Investments SE
Carlson Investments SE, listed on Warsaw’s NewConnect and the German Open Market (Frankfurt, Munich, Stuttgart, Gettex), supports high-growth early-stage tech ventures across healthtech, AI, fintech, and deeptech. Carlson applies a hands-on investment approach and integrates its portfolio companies into a global network of strategic partnerships.

Risk Disclaimer
This announcement • does not constitute investment advice or a solicitation to buy or sell financial instruments • involves risks, including possible loss of capital • does not guarantee future earnings • past performance is not indicative of future results.

WE ARE PUBLICLY LISTED, YOU CAN BUY OUR SHARES ON:
Warsaw Stock Exchange (PLN): CAI, PLHOTB000011
Frankfurt Stock Exchange (EUR): 2HB (FRA), PLHOTB000011
Munich Stock Exchange (EUR): 2HB (MUN), PLHOTB000011
Stuttgart Stock Exchange (EUR): 2HB (STU), PLHOTB000011
GETTEX Exchange (EUR): 2HB (GET), PLHOTB000011
WKN: A0RNWQ

Press Contact:
Management Office
Carlson Investments SE
[email protected]
www.carlsonvc.com